Drug of Choice for Candidal Endocarditis
For initial therapy of Candida endocarditis, use either lipid formulation amphotericin B 3-5 mg/kg daily (with or without flucytosine 25 mg/kg four times daily) OR high-dose echinocandin (caspofungin 150 mg daily, micafungin 150 mg daily, or anidulafungin 200 mg daily), combined with early valve replacement surgery. 1
Initial Antifungal Therapy
The IDSA guidelines provide two equally acceptable first-line options for native valve Candida endocarditis 1:
- Lipid formulation amphotericin B 3-5 mg/kg daily ± flucytosine 25 mg/kg four times daily
- High-dose echinocandin: caspofungin 150 mg daily, micafungin 150 mg daily, or anidulafungin 200 mg daily
The rationale for these choices is based on superior biofilm penetration compared to standard-dose antifungals. Echinocandins and lipid formulations of amphotericin B demonstrate more potent activity against Candida biofilms in vegetations, whereas amphotericin B deoxycholate and azoles penetrate poorly into vegetations 1. Higher echinocandin doses are specifically necessary to treat endocarditis effectively 1.
Critical caveat: Fluconazole monotherapy is associated with unacceptably high relapse and mortality rates and should never be used as initial therapy 1.
Surgical Management
Valve replacement is strongly recommended and should be performed early 1. The optimum therapy for both native and prosthetic valve endocarditis combines valve replacement with prolonged antifungal therapy 1. Medical therapy alone has occasionally been curative but carries substantially higher mortality 1.
Antifungal treatment should continue for at least 6 weeks after surgery, with longer duration required for perivalvular abscesses and other complications 1.
Step-Down Therapy
After clinical stability is achieved and bloodstream clearance is documented, transition to fluconazole 400-800 mg (6-12 mg/kg) daily for fluconazole-susceptible isolates 1.
For isolates resistant to fluconazole but susceptible to other azoles, use voriconazole 200-300 mg (3-4 mg/kg) twice daily or posaconazole tablets 300 mg daily 1.
Special Situations
Patients Unable to Undergo Surgery
For patients who cannot undergo valve replacement, long-term suppression with fluconazole 400-800 mg (6-12 mg/kg) daily (if susceptible) is recommended to prevent relapse 1.
Prosthetic Valve Endocarditis
Use the same antifungal regimens as for native valve endocarditis 1. Chronic suppressive antifungal therapy with fluconazole 400-800 mg (6-12 mg/kg) daily is mandatory to prevent recurrence, as prosthetic valve infections have exceptionally high relapse rates 1.
Common Pitfalls to Avoid
- Never use fluconazole as initial monotherapy - this is associated with unacceptably high mortality 1
- Do not use standard echinocandin doses - endocarditis requires higher doses (150 mg caspofungin, 150 mg micafungin, or 200 mg anidulafungin) 1
- Do not delay surgery - medical therapy alone has poor outcomes; early valve replacement is critical for survival 1
- Maintain long-term follow-up - Candida endocarditis has a propensity to relapse months to years later 1
Duration and Monitoring
Total treatment duration depends on surgical intervention and complications, but typically extends several months 1. Blood cultures should be monitored to document clearance before step-down therapy 1. Follow-up should be maintained for several years after treatment completion due to late relapse risk 1.